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Abstract
Background: Trauma induces local and subsequent systemic inflammatory reactions, and when the cytokine
production is deregulated, a systemic inflammatory response syndrome with a potentially lethal outcome can
occur. The understanding of the physiological mechanism of the cytokine network would be useful to better
comprehend pathological conditions.
Methods: We analysed a panel of 30 cytokines in the serum of 20 patients operated with total hip replacement.
Cytokine release was assessed postoperatively up to 6 days by a multiplex antibody bead kit and compared to
pre-operative values.
Results: Surgery induced significant increments in serum levels of IL-2R at 6 days after surgery, in levels of IL-6 at
6 hours after surgery and at 1 day after surgery, in levels of IL-8 at 6 hours after surgery, in levels of IL-16 at 6 hours
and at 1 day after surgery. Significant decreases in serum levels of IL-1Rα were found at the end of surgery, in levels
of IL-12 at the end of surgery and at 6 hours after, and in levels of Eotaxin during all phases of the postoperative
course.
Conclusions: The major findings were significant increases in systemic levels of the pro-inflammatory cytokines
IL-6, IL-8, IL-16, while IL-12 was significantly decreased. Otherwise there were modest changes in the systemic
cytokine kinetics and no significant expression of anti-inflammatory cytokines.
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Background
Inflammatory cells that contribute to clearance and re-
pair of necrotic tissue dominate the local response to in-
jury [1]. These cells release soluble molecules, mainly
cytokines, which generally function as intercellular mes-
sengers in an autocrine mode by binding to the cell of
their origin or in a paracrine mode by binding to recep-
tors on neighboring target cell [2].
Cytokines also act at sites distant from the origin of
their production, and a systemic acute-phase response ac-
companies the local inflammation. This is followed by a
compensatory anti-inflammatory response to attenuate
the proinflammatory state [3], and the balance between
the pro- and anti-inflammatory responses determines the
net effect of an inflammatory response. In major injury
disequilibrium between the pro- and anti-inflammatory
responses may initiate a generalized response that in turn
may progress to a multiple organ dysfunction [4].
Animal and human experiments have suggested the
possibility of modifying the host inflammatory response,
but clinical trials have been almost uniformly unsuccess-
ful. The body’s response to trauma is a highly complex
and heterogeneous sequence of events [5], and specific
cytokine patterns, truly predictive of outcomes, are yet
to be established. A difficulty has been in differentiating
actual mediators of inflammation from inactive markers
of inflammation. Thus, trauma models are required to
provide a rational framework for the design of future
clinical observational studies. We therefore sought to de-
fine the systemic release patterns of a broad panel of cy-
tokines in a major standardized musculoskeletal trauma
like total hip replacement.
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Methods
The study was approved by the Regional ethics committee
and was performed in accordance with the ethical stan-
dards of the Declaration of Helsinki. After signed informed
consent, 12 women and 8 men aged above 50 years that
underwent primary cemented total hip arthroplasty
(THA) due to osteoarthritis were included. All patients re-
ceived spinal anesthesia without hypotensive effect with
5 mg/mL bupivacaine (Marcain®; AstraZeneca, Södertälje,
Sweden) injected at the lumbar level.
We used thromboprophylaxis with low-molecular-
weight heparin (dalteparin, ‘Fragmin’®; Pharmacia &
Upjohn, Stockholm, Sweden) and infectious prophylaxis
with cephfalothin (Keflin®; Eli Lilly, Indianapolis, IN.,
USA). Voluven® and Ringer’s acetate (Fresenius KABI, Bad
Homburg, Germany) were used as plasma substitutes. The
operation was performed in the lateral position, using a
standardized posterior approach. Postoperative analgesia
was administered according to a standard protocol consist-
ing of paracetamol and codeine sulphate (Paralgin forte®;
Weifa AS, Oslo, Norway) and ketobemidon (Ketorax®;
Jenahexal Pharma, Jena, Germany). Closed postoperative
drainage was used for 24 hours. All patients were mobi-
lized on the first postoperative day.
Patients with allergy to dalteparin, bleeding disorders,
renal failure, hepatic disease, active treatment for malig-
nancy, on-going antithrombotic treatment, history of
deep vein thrombosis or pulmonary embolus, and pa-
tients experiencing major operations, traumas, stroke, or
cardiac infarction the last 3 months before surgery were
excluded. Patients were advised to stop antiplatelet medi-
cation 1 week before surgery.
Hemoglobin, hematocrit, white blood counts, platelet
counts, c-reactive-protein, creatinin, and liver enzymes
were analyzed the day before surgery.
Blood samples were obtained from peripheral veins at
the following time points: (T1) before induction of
anesthesia, (T2) at the end of surgery, (T3) 6 hours after
surgery, (T4) the day after surgery, and (T5) 6 days after
surgery. Blood samples was kept on ice until it was
separated by centrifugation at 2500 g for 20 min at 18
degrees C and stored at -80 degrees C until assayed. The
concentration of cytokines in the blood samples was de-
termined by a multiplex antibody bead (Chemokine/
Cytokine 30-Plex, Biosource, Camarillo, CA, USA) and
were simultaneously measured in the Luminex-100 sys-
tem according to the manufacturer’s instructions. The
acquired fluorescence data were analyzed by Starstation
software (version 2.0; Applied Cytometry Systems, Shef-
field, United Kingdom).
Statistical analyses were performed using SPSS II soft-
ware Version 19 (IBM Inc. USA). Data are presented by
mean and standard deviation. Time dependent changes
were performed by analysis of variance (ANOVA). If sig-
nificant differences were indicated, we used the LSD
post hoc test. P ≤ 0.05 was considered significant. Corre-
lations were carried out with Pearson correlation.
Results
The operative time ranged from 44 to 119 minutes with a
mean of 68 minutes, and the postoperative course was un-
eventful in all patients up to 6 days after surgery when
they left the hospital. Surgery induced significant incre-
ments in serum levels of Interleukin-2 receptor (IL-2R) at
6 days after surgery (p = 0.014), in levels of IL-6 at 6 hours
after surgery (p = 0.020) and at 1 day after surgery (p =
0.003), in levels of IL-8 at 6 hours after surgery (p = 0.006)
and in levels of IL-16 at 6 hours after surgery (p = 0.019)
and at 1 day after surgery (p = 0.002) (Table 1). Significant
decreases in serum levels of IL-1 receptor alpha (IL-1Rα)
were found at the end of surgery (p = 0.044), in levels of
IL-12 at the end of surgery (p = 0.047) and at 6 hours after
surgery (p = 0.018) and in levels of Eotaxin during all
phases of the postoperative course (p = 0.018, 0.001,
<0.001 and 0.005, respectively).
In the postoperative course up to 6 days there were no
significant changes in serum levels of IL-1β, IL-2, IL-5, IL-
7, IL-10, IL-13, IL-15, IL-17, Tumor necrosis factor alpha
(TNF-α ), Interferon alpha (INF-α), Interferon gamma
(INF-γ), Granulocyte macrophage colony-stimulating
Table 1 Changes in serum cytokines (pg/mL)
T1 T2 T3 T4 T5 ANOVA
Il-1Rα 441 ± 118 345 ± 125a 363 ± 191 398 ± 119 498 ± 189 0.011
Il-2R 231 ± 70 179 ± 66 187 ± 86 231 ± 67 346 ± 29b 0.003
Il-6 13 ± 33 14 ± 27 33 ± 23c 41 ± 29d 22 ± 26 0.008
Il-8 8.9 ± 4.3 10.0 ± 4.7 18.2 ± 22e 10.4 ± 4.7 15.1 ± 6.4 0.028
Il-12 135 ± 38 106 ± 37f 100 ± 46g 111 ± 36 141 ± 67 0.018
Il-16 0.3 ± 0.9 0.6 ± 0.8 1.0 ± 0.7h 1.2 ± 1.0i 0.7 ± 0.9 0.010
Eotaxin 66 ± 20 50 ± 25j 44 ± 26k 38 ± 18l 47 ± 16 m 0.001
Time points are before induction of anaesthesia (T1), at the end of surgery (T2), at 6 hours after surgery (T3), at the day after surgery (T4), and at 6 days after
surgery (T5). Values are mean ± standard deviation.
ap = 0.044, bp = 0.014, cp = 0.020, dp = 0.003, ep = 0.006, fp = 0.047, gp = 0.018, hp = 0.019, ip = 0.002, jp = 0.018, kp = 0.001 lp = <0.001, mp = 0.005 in relation
to T1.
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factor (GM-CSF), Macrophage inflammatory protein 1
alpha (MIP-1α) and 1 beta (MIP-1β), Interferon gamma-
induced protein 10 (IP-10), Monokine induced by inter-
feron gamma (MIG), Regulated on Activation, Normal T
Cell Expressed and Secreted (RANTES), monocyte
chemotactic protein 1 (MCP-1), Epidermal growth factor
(EGF), Granulocyte colony-stimulating factor (G-CSF),
Fibroblast growth factor (FGF), Hepatocyte growth factor
(HGF) and Vascular endothelial growth factor (VEGF)
(Table 2).
We found no significant correlations between IL-6 and
the patient’s clinical parameters sex (R = 0.049), body mass
index (R = 116) or American Society of Anesthesiologists
score (R = 116), while there was a significant (p = 0.005)
correlation between IL-6 and age (R = - 0.327).
Discussion
In this study we characterized a large panel of systemic
cytokines in order to know if and how much these mole-
cules are regulated in case of a major, but standardized
musculoskeletal injury. Our main focus was effects of
surgery on these changes, rather than a comparison to a
reference or control group, and the preoperative levels
therefore were used as references. THA creates a patho-
physiological condition that resembles the clinical char-
acteristics of polytrauma, and since bacterial infections
were absent at the time of surgery, the immune response
was triggered by endogenous stimuli. The major observa-
tions were significantly increases in the proinflammatory
cytokines IL-6, IL-8 and IL-16 in the postoperative course.
These mediators were insignificantly increased at the end
of surgery, while IL-1Rα, IL-2R and IL-12 were decreased
at this time point. These observations probably reflect he-
modilution during major surgery, and our findings sup-
port the concept that a major musculoskeletal trauma is
associated with a restricted cytokine response in the sys-
temic circulation [6].
It is important to identify inflammatory markers so as
to use them as possible targets for the development of
new pharmacological approaches in trauma patients.
However, traumatically injured patients are exhibiting
a host response to pain, and hemorrhage may be
Table 2 Changes in serum cytokines (pg/mL)
T1 T2 T3 T4 T5 ANOVA
IL-1β 9.2 ± 20 4.7 ± 12 4.5 ± 12 4.3 ± 13 12 ± 21 0.421
IL-2 3.3 ± 8.3 1.5 ± 3.8 1.3 ± 2.5 1.9 ± 4.9 3.6 ± 7.1 0.969
IL-5 9.3 ± 11 9.2 ± 11 12 ± 11 11 ± 11 9.2 ± 11 0.934
IL-7 22 ± 21 16 ± 20 15 ± 18 19 ± 19 27 ± 20 0.500
IL-10 22 ± 53 16 ± 38 15 ± 42 17 ± 39 16 ± 37 0.989
IL-13 7.8 ± 6.2 6.2 ± 5.9 7.8 ± 6.5 7.7 ± 6..4 8.1 ± 7.3 0.711
IL-15 70 ± 29 60 ± 28 62 ± 29 63 ± 26 81 ± 39 0.175
IL-17 0.6 ± 2.5 0.1 ± 0.2 1.0 ± 3.4 0.1 ± 0.1 1.2 ± 3.5 0.446
TNF-α 0.9 ± 1.7 0.6 ± 1.1 0.6 ± 0.7 0.7 ± 0.9 0.8 ± 1.1 0.947
INF-α 43 ± 21 2 9 ± 21 26 ± 24 36 ± 24 44 ± 21 0.182
INF-γ 15 ± 13 15 ± 14 14 ± 13 14 ± 14 20 ± 15 0.904
GM-CSF 106 ± 223 77 ± 182 4 5 ± 115 80 ± 182 86 ± 183 0.918
MIP-1α 50 ± 22 45 ± 20 44 ± 36 47 ± 22 53 ± 17 0.785
MIP-1β 44 ± 20 42 ± 25 53 ± 37 56 ± 27 55 ± 21 0.356
IP-10 243 ± 139 213 ± 119 214 ± 165 187 ± 128 314 ± 272 0.230
MIG 41 ± 27 27 ± 19 28 ± 28 29 ± 21 35 ± 23 0.361
RANTES 3489 ± 2072 2972 ± 2565 3002 ± 3874 3154 ± 2963 4553 ± 3501 0.607
MCP-1 229 ± 55 199 ± 48 293 ± 112 221 ± 84 248 ± 59 0.147
EGF 1.7 ± 2.8 0.9 ± 1.6 2.8 ± 6.3 1.1 ± 1.6 2.4 ± 2.8 0.368
G-CSF 113 ± 59 89 ± 66 92 ± 99 104 ± 64 119 ± 64 0.603
FGF 18 ± 24 13 ± 24 13 ± 16 14 ± 16 18 ± 16 0.764
HGF 89 ± 27 64 ± 23 114 ± 68 156 ± 96 134 ± 36 0.577
VEGF 3.4 ± 4.0 3.2 ± 3.9 4.1 ± 4.0 3.5 ± 4.2 3.7 ± 3.9 0.949
Time points are before induction of anaesthesia (T1), at the end of surgery (T2), at 6 hours after surgery (T3), at the day after surgery (T4), and at 6 days after
surgery (T5). Values are mean ± standard deviation.
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superimposed to produce shock, which may enhance the
physiological and immunologic responses. It is therefore
clear that traumatized and surgical patients cannot be con-
sidered similarly under a generic category of inflammation.
The production of cytokines is transient, and since the
efficiency is high, their activities have to be tightly con-
trolled. The biological activities of cytokines are modu-
lated by several different, but highly specific strategies,
which involve inhibitory cytokines, soluble receptors and
receptor antagonists. Then, cytokines may be character-
ized as either proinflammatory or anti-inflammatory
based on their predominant action. However, it should
be noted that the common and clear-cut classification of
cytokines as either pro or anti-inflammatory might be
misleading. The type, duration, and also the extent of
cellular activities induced by one particular cytokine can
be influenced considerably by the nature of the target
cells, the micro-environment of a cell, the type of neigh-
boring cells, cytokine concentrations, the presence of
other cytokines, and even on the temporal sequence of
several cytokines acting on the same cell. Also the age of
the patients may to some extent influence the cytokine
response. We found a significant, but poor correlation to
age.
The pro-inflammatory cytokines TNF-α and IL-1β
have in general been considered to be responsible for
the non-hepatic manifestations of the acute-phase re-
sponse, and to stimulate the release of other cytokines,
including IL-6 [7-9]. Our investigation, like others [6,10],
questions the use of TNF-α and IL-1β as clinical
markers of traumatic inflammation. In contrast, a direct
relationship has been confirmed between elevated levels
of IL-6 and IL-8 and degree of injury [11-14]. IL-6 is the
principal regulator of most acute-phase protein genes
and regulates local and systemic inflammatory re-
sponses, including the synthesis of hepatic acute-phase
reactants like C-reactive protein [15,16]. We found that
IL-6 levels were increased at 4 h and at 1 day after sur-
gery. This is in agreement with a previous study in stable
trauma patients [17]. Sustained high levels of IL-6 have
been associated with increased severity of tissue injury
and have correlated with subsequent development of
post injury complications [18,19].
The increases in IL-8 were short-lived at 6 hour after
surgery and reflect that IL-8 is a chemokine that attracts
polymorphonuclear neutrophil cells and macrophages
into the wound site [20]. Typically, at 24 h the neutro-
phil population is at its maximum, and the activity of
these neutrophils may play a critical role in recovery. In
a study evaluating clinical outcome in children follow-
ing blunt trauma, serum IL-8 level at admission was
identified as the most important determinant of post
injury mortality [21] On the other hand, Eotaxin, a
chemoattractant cytokine for eosinophiles, was reduced
in the postoperative course. These observations prob-
ably reflect the interplay by different inflammatory cells
following a musculoskeletal injury.
IL-16 is produced by different cell types and acts
as an immunomodulatory cytokine, which induces
lymphocyte migration, expression of proinflammatory
IL-1β, IL6 and TNF-α and modulates apoptosis
[22,23]. It is expressed in a variety of pathologic condi-
tions [24], and after trauma plasma IL-16 levels was
transiently increased as compared with non-injured
controls [25]. High levels immediately after injury sug-
gest that IL-16 may be a component of the acute phase
response. However, in those with worse outcome the
levels were lower than in less severely injured patients.
In vitro experiments have shown that lower concentra-
tions of IL-16 stimulate monocyte secretion of inflam-
matory cytokines, whereas higher amounts seem to
have inhibitory effects [26]. Then, higher levels of IL-
16 following injury may suppress the peripheral adap-
tive immune response, which may protect the injured
patient from the consequences of an exaggerated
response.
IL-12 is known to be the principal agent that induces
naive T-helper cells to assume the Th1 phenotype [27].
Our results are in agreement with previous reports that
injury in humans is followed by a diminished capacity to
produce IL-12 by peripheral mononuclear cells [28,29].
This may explain at least in part the apparent inability
to maintain Th1 function and cytokine production
which has been noted in clinical studies approximately
1 week after serious injury. Depressed capacity for IL-12
production has correlated with the development of mul-
tiorgan failure [30]. These findings are also in concert
with those of a recent report showing diminished IL-12
production in patients in whom sepsis developed after
gastrointestinal surgery [31].
In humans, a reciprocal relation between diminished
IL-12 production and increased IL-10 production has
been shown at approximately 1 week after injury [31].
Traditionally IL-10 has been considered a main antiin-
flammatory cytokine since septic complication after
trauma has been associated with increased levels of this
cytokine. In our patients no anti-inflammatory cytokines
were increased. On the contrary the anti-inflammatory
cytokines IL-1RA were decreased immediately post sur-
gery, but this was probably due to hemodilution. IL-2R
was increased at 6 days after surgery. IL-2 is known to
enhance dopaminergic transmission and serves as a neu-
romodulatory molecule [32], and an increase in IL-2R
may reflect post injury interplay between this proinflam-
matory cytokine and its soluble receptor. However, it
should be emphasized that the increases in IL-2R were
modest, and at 6 days after surgery, the increase may be
questioned.
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Conclusions
We conclude that a major, but controlled musculoskeletal
trauma is followed by significant increases in the proin-
flammatory cytokines IL-6, IL-8 and IL-16 and significant
decreases in IL-12 and Eotaxin. Otherwise there were
modest changes in the systemic cytokine kinetics and no
significant expression of anti-inflammatory cytokines.
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